10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

March 23, 2022

Study Completion Date

March 23, 2022

Conditions

HIV-1-infection

Interventions

BIOLOGICAL

10E8.4/iMab

bispecific monoclonal antibody

Trial Locations (2)

Columbia University Research Unit, New York

Orlando Immunology Center, Orlando

All Listed Sponsors

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

International AIDS Vaccine Initiative

NETWORK

collaborator

The Emmes Company, LLC

INDUSTRY

lead

David Ho

OTHER

NCT03875209 - 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults | Biotech Hunter | Biotech Hunter